Category: Press Release
-
April 2nd, 2024: Ratio Strengthens its Leadership Team with the Appointments of Bill Cupelo as Chief Business Officer and D. Scott Holbrook to its Board of Directors
BOSTON, April 2, 2024 – Ratio Therapeutics Inc. (Ratio), an emerging pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced the appointments of Bill Cupelo as the company’s Chief Business Officer and D. Scott Holbrook, MS, FSNMMI-TS to its Board of Directors. These strategic additions to Ratio’s leadership…
-
March 12th, 2024: Ratio Announces Expansion of Manufacturing Agreement with PharmaLogic for FAP-Targeted Radiopharmaceuticals
BOSTON, MA and BOCA RATON, FL – March 12th, 2024 – Ratio Therapeutics Inc. (Ratio), an emerging pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced an expanded manufacturing agreement with PharmaLogic, a world-class contract development and manufacturing organization (CDMO) specializing in radiopharmaceutical production and distribution. The collaboration…
-
January 17th, 2024: Ratio Therapeutics Announces $50M Series B Financing to Advance Targeted Radiotherapies for Cancer Treatment
Boston-Based Radiopharmaceutical Company Brings Total Financing to More Than $90Million Since 2021 Launch BOSTON, January 17, 2024 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class radiopharmaceuticals for the treatment and monitoring of cancers, today announces the close of its $50M Series B financing, bringing the…
-
July 11th, 2023: Ratio Therapeutics, In Collaboration with Lantheus and PharmaLogic, Announce First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging
A collaboration to advance development of a fibroblast activation protein (FAP)-targeted PET diagnostic compound for a broad array of epithelial-derived cancers. BOSTON, July 11th, 2023 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class radiopharmaceuticals for the monitoring and treatment of cancers today announced, in partnership with…
-
May 9th, 2023: Ratio Therapeutics Announces Opening of New Research and Development Facility
Boston-based fast-growing radiopharmaceutical company opens the doors to its new headquarters and research facility to advance targeted radiotherapies for cancer BOSTON, May 9, 2023 – Ratio Therapeutics Inc., a pharmaceutical company focused on developing innovative radiopharmaceuticals for the treatment of cancer, is pleased to announce the opening of its new 19,000-square-foot headquarters and R&D facility in…
-
March 28th, 2023: Ratio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with Merck
Collaboration to develop a Granzyme B-targeted agent for PET imaging applications in inflammation and cancer indications BOSTON, March 28, 2023 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class radiopharmaceuticals for the monitoring and treatment of cancers, today announced the licensing of a Granzyme B-targeted agent for PET…
-
March 13th, 2023: Ratio Therapeutics Appoints Dr. Noel Monks as Head of Biology
BOSTON, March 13, 2023 /PRNewswire/ — Ratio Therapeutics Inc. (Ratio), a pharmaceutical company specializing in the development of targeted radiotherapeutics for the treatment of cancer, today announced the appointment of Dr. Noel Monks as the company’s Head of Biology. Dr. Monks joins Ratio with over 20 years of experience in drug discovery, development, and translational medicine in the fields of…
-
February 1st, 2023: Ratio Therapeutics Announces $20M Series A Financing to Advance Targeted Radiotherapies for Cancer Treatment
Boston-Based Pharmaceutical Company Brings Total Financing to More Than $40 Million since 2022 Launch Dr. Susan K. Whoriskey, Ph.D., to Join the Company’s Board of Directors as Strategic Advisor BOSTON, February 1, 2023 – Ratio Therapeutics Inc., a pharmaceutical company specializing in the development of targeted radiotherapeutics for the treatment of cancer, announces the close of…
-
December 6th, 2022: Ratio Therapeutics Appoints Reed Malleck as Chief Financial Officer
BOSTON, December 6, 2022 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancers, today announced the appointment of Reed Malleck as the company’s Chief Financial Officer (CFO). Mr. Malleck comes to Ratio with more than 25 years of finance and…
-
September 15th, 2022: Ratio Therapeutics Appoints Jacob Hesterman, Ph.D., as Chief Data Officer
BOSTON, September 15, 2022 – Ratio Therapeutics Inc., a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancers, today announced the appointment of Jacob Hesterman, Ph.D., as the company’s Chief Data Officer (CDO). In this newly created role, Dr. Hesterman will build the company’s data management…